FDA-Backed AI Uses Retinal Scans to Predict Heart Disease Risk in Seconds

A new AI system called CLAiR is changing how doctors assess heart disease risk. By analysing retinal images, it quickly predicts cardiovascular dangers with high accuracy. The technology has now earned recognition from the U.S. Food and Drug Administration (FDA). CLAiR works by scanning retinal photos, a process that takes around five minutes. The AI then delivers a risk estimate in roughly 30 seconds. Its predictive power outperforms standard risk calculators, with a sensitivity of 91.1% and a specificity of 86.2%.

A multi-centre study involving 874 participants confirmed the system's safety and effectiveness. Unlike manual reviews, CLAiR's automated analysis is faster and more scalable. However, it is not meant to replace full medical evaluations but to encourage further testing. The device is designed to fit smoothly into existing healthcare routines. Yet, its use is limited for patients with severe eye disease or those who are pregnant. While retinal imaging is widely available in U.S. eye clinics, insurance coverage for these scans remains uneven. The FDA has granted CLAiR its Breakthrough Device designation, highlighting its potential impact. Still, details about participating clinics or patient recruitment in the validation study have not been publicly disclosed.

CLAiR offers a rapid, AI-driven way to flag cardiovascular risks using routine eye scans. Its high accuracy and FDA recognition could improve early detection. However, broader adoption may depend on clearer insurance policies and wider clinical integration.